Leukemia

Bone marrow makes the cells that become red cells, white cells, and platelets. In leukemia, one line of those cells grows abnormally and crowds out the rest. Acute myeloid leukemia and acute lymphoblastic leukemia move quickly and can make someone seriously unwell in days or weeks. Chronic myeloid leukemia and chronic lymphocytic leukemia often move more slowly. There are other, rarer, marrow cancers nearby, including myelodysplastic syndromes, which are not leukemia but can lead to it. The name on the marrow report is what treatment follows.

Lymphoma is a related but separate group of blood cancers and has its own page. A high white cell count can be leukemia, and it can also be infection, steroids, or smoking. A low count can be leukemia, a deficiency, or a drug effect. Numbers need a blood film and, usually, a bone marrow test before anyone uses the word leukemia with confidence.

Acute leukemia can cause tiredness from anaemia, infections from a lack of healthy white cells, bleeding or bruising from low platelets, fever, bone pain, and sometimes swollen gums or nodes. These need prompt hospital assessment. Waiting for an outpatient appointment is the wrong pace if bleeding, fever, or severe breathlessness is already present. Use emergency care for those symptoms and say that a blood count was abnormal if you know that.

Chronic leukemias are often found when a blood count was done for another reason and the person feels well. Swollen nodes, night sweats, fullness under the left ribs from an enlarged spleen, or gradual tiredness can occur. An abnormal count still needs a specialist. It does not always need treatment the same week. The difference between urgent and watchful is a medical decision made from the type of leukemia, not from how frightening the word sounds.

A full blood count and a look at the blood film are the start. Bone marrow aspiration and biopsy show which cells are abnormal and how much of the marrow they occupy. Flow cytometry identifies the cell type. Chromosome and molecular tests look for changes such as the Philadelphia chromosome in chronic myeloid leukemia, FLT3 or other mutations in acute myeloid leukemia, and the markers that risk-stratify acute lymphoblastic leukemia. Those results change the medicines. Starting treatment without them is sometimes necessary in an emergency. That is a hospital decision, not a website decision.

Other tests look at infection risk, heart function before certain drugs, and whether the brain or testes need separate assessment in some acute lymphoblastic leukemias. HLA typing, a tissue-matching blood test, is done early when a transplant might later be needed, so a donor search is not delayed. Doing the test does not mean a transplant will happen. It means the option stays open.

Acute leukemia is usually treated in a unit that can support very low blood counts with transfusions and antibiotics. The first phase, called induction, aims to clear visible leukemia from the marrow. Later phases, called consolidation, reduce the chance of return. Chemotherapy is the backbone for many people. Targeted drugs are added when a mutation such as FLT3 is present, or in other defined situations. Acute promyelocytic leukemia is a specific subtype with a different, highly specialised treatment and is a medical emergency of its own. It should be named clearly on the report if that is what you have.

Chronic myeloid leukemia is often treated with a targeted tablet aimed at BCR-ABL. Most people take it for many years. Blood tests and, at intervals, a molecular test measure the response. Missing doses matters. So do interactions with ordinary medicines. Chronic lymphocytic leukemia may be observed for years. When treatment is needed, targeted tablets or antibody combinations are commonly used. Older chemotherapy is less often the first choice than it once was. The right moment to start is based on counts, symptoms, and stage, not on the mere presence of the disease.

A stem cell transplant, using a donor or sometimes the person’s own cells depending on the disease, is considered for selected high-risk or relapsed leukemia. It can be curative and it can also cause serious complications, including graft-versus-host disease. It is not offered to every person with leukemia. Age, fitness, donor availability, and the genetic risk of the leukemia all enter the decision. Dr. Nishith Vaddeboina’s published experience includes peripheral blood stem cell transplants. Whether a transplant is appropriate still depends on the current reports, not on a general statement.

Low white cells mean a fever can become life-threatening quickly. You should leave hospital with a number to call and a threshold, often a single high temperature, for coming back. Bleeding, black stools, chest pain, or confusion are also urgent. Tablets for chronic leukemias can cause rash, muscle cramps, swelling, liver changes, or heart-rhythm effects depending on the drug. Blood tests continue even when you feel well. Do not stop a targeted tablet because a blood count looks normal. That result may be the drug working.

Infection precautions, safe food handling, and avoiding crowded places are most important when counts are low. Transfusions are supportive. They do not treat the leukemia by themselves. Fertility, work, and who will stay with you during induction should be discussed early. Emotional strain on the family is expected. Social support is part of getting through intensive treatment, not a luxury beside it.

After acute leukemia, marrow tests and blood counts look for residual disease. A molecular marker, if one was found at diagnosis, can show very small amounts of leukemia returning before the counts fall. That information can trigger a change in treatment. It is interpreted by the team. A single number out of context is not a reason to panic or to ignore. Chronic myeloid leukemia follow-up is built around the molecular response. Some people later discuss a carefully supervised stop of the tablet. That is a specialist decision with close monitoring. It is not something to try alone.

If leukemia returns, the next treatment depends on how long the first response lasted, which drugs were used, and the genetic results at relapse. A transplant may be reconsidered. A clinical trial may be relevant. Comfort-focused care is also a valid plan when intensive treatment is unlikely to help or is not what the person wants. Those are explicit conversations. They should include the people who will live with the decision.

Bring every blood count, the marrow report, flow cytometry, and genetic results if they already exist. Add transfusion dates and the names of tablets you have started. If you have been unwell with fever, say so at the start of the visit. Acute leukemia can move too quickly for a routine slot. If you are bleeding, severely short of breath, or febrile now, go to emergency care and arrange the consultation after you are safe.

A visit about leukemia is used to read the records you already have, explain them in plain language, and outline options that may apply. Bring the biopsy or pathology report, scan CDs or reports, blood tests, and a list of treatment already given, including dates and drug names if you have them. A family member can come with you. The visit is not an emergency assessment, and it does not confirm a plan until the records have been reviewed.

Dr. Nishith Vaddeboina is a medical oncologist. Appointments published on this website are at American Oncology Institute, Nallagandla, Hyderabad. The biography also lists consultant work at Renova Century Hospitals. Confirm the hospital when you book. Plans are discussed against recognised guidance, including NCCN, ESMO, and ASCO, and then adjusted to the person in the room. Nothing on this page replaces that conversation.

Fever, bleeding, severe breathlessness, or a blood count that a laboratory has flagged as urgent need same-day care. A mildly abnormal count found on a routine test needs a prompt clinic review, not an emergency dash and not months of delay. This page cannot read a blood report.